Christophe Bourdon, Leo Pharma CEO

Fur­ther shuf­fling at Leo Phar­ma as der­ma­tol­ogy drug­mak­er splits R&D

Dan­ish der­ma­tol­ogy drug­mak­er Leo Phar­ma said it will split its R&D op­er­a­tions in­to two sep­a­rate teams.

The com­pa­ny had about 6,000 em­ploy­ees in ear­ly 2022 but, at the time, said it would elim­i­nate 1,000 po­si­tions in two years. Then, this Jan­u­ary, Leo said it would fur­ther re­duce head­count by about 300 po­si­tions in a re­hash­ing of its sourc­ing mod­el to em­pha­size ex­ter­nal help in find­ing orals, top­i­cals and bi­o­log­ics. Leo now says it em­ploys 4,700 peo­ple world­wide.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.